Physician profile

Bryan W Kluck

Cardiovascular Disease · Allentown, PA

NPI 1659486959

$60,281.56

in general payments reported to CMS, 2019-2025

38 companies · $331 in 2025

The $331 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Long Term Medical Supply Or Device Loan$3,541.67
Food and Beverage$3,064.04
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$2,800.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $23,550.01 2019-2024 Xarelto
Boston Scientific Corporation $13,858.26 2019-2024 Watchman Access System, Jetstream Sc, Varithena Administration Pack
Chiesi USA, INC. $5,524.83 2019-2021
Abiomed $4,658.67 2019-2022
Angiodynamics, INC. $3,541.67 2023 Auryon Laser System 100-120 Vac
Medtronic, INC. $3,024.87 2021-2024 Venaseal, Linq II
Portola Pharmaceuticals, LLC $2,486.54 2019
Biotronik INC. $506.05 2019-2025 Orsiro Mission, Nhancer Rx, Recross
Tactile Systems Technology INC $412.46 2023-2025 Flexitouch Plus, Entre Plus, Nimbl
Novartis Pharmaceuticals Corporation $325.92 2019-2025
Abbott Laboratories $315.41 2019-2025 Xience Skypoint, Diamondback Coronary, Jeti Peripheral Catheter
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $234.90 2019-2024 Lifevest
E.R. Squibb & Sons, L.L.C. $223.99 2020-2024 Camzyos
Medtronic Vascular, INC. $185.90 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $154.42 2023-2025 Jardiance
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Bard Peripheral Vascular, INC. $125.27 2022-2023 Venovo
Astrazeneca Pharmaceuticals LP $121.03 2023-2024 Farxiga
Cardiovascular Systems INC. $117.65 2019
Esperion Therapeutics, INC. $113.18 2024-2025 Nexletol
Amgen INC. $112.49 2023-2025 Repatha, Repatha
Kiniksa Pharmaceuticals International, Plc $98.99 2024 Arcalyst
Philips North America LLC $81.24 2023
Actelion Pharmaceuticals US, INC. $75.68 2023-2025 Opsumit, Opsynvi, Uptravi
Edwards Lifesciences Corporation $73.03 2019-2021
Pfizer INC. $71.21 2023-2024
Novo Nordisk INC $58.00 2023-2024 Wegovy, Rybelsus, Ozempic
Reflow Medical INC $37.35 2024
Infobionic, INC $26.50 2023 Mome Kardia
Merck Sharp & Dohme LLC $22.34 2025 Verquvo
Kowa Pharmaceuticals America, INC. $20.39 2024 Livalo
Inari Medical, INC. $20.38 2020
Glaxosmithkline, LLC. $19.10 2019
Bayer Healthcare Pharmaceuticals INC. $18.71 2025
Daiichi Sankyo INC. $16.99 2023 Injectafer
Cardiva Medical, INC. $16.83 2022
Braemar Manufacturing, LLC $16.15 2019
Cashflow Solutions, LLC $15.15 2025 Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Bryan W Kluck

$60,281.56

in general payments reported 2019-2025

Years
2019-2025
Top company
Janssen Pharmaceuticals, INC
Context
The $331 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/257246/bryan-w-kluck

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.